Vibiosphen
Created in 2014
- BETA
Up & running (A)
Existing signals show a regular activity Social networks
235 1,276Activities
Technologies
Entity types
Location
516 Rue Pierre et Marie Curie, 31670 Labège, France
Labège
France
Employees
Scale: 2-10
Estimated: 8
SIREN
804167666Engaged corporates
4
2 2Added in Motherbase
5 years ago
biotech Value proposition
From Microbes to One Health. Taylor made R&D to tackle infectious diseases.
Vibiosphen is a SME healthcare biotechnology in infectious diseases founded in 2014.
Given the important and interdependent human, animal, and environmental dimensions of antimicrobial resistance, the One Health concept promotes a global effort to achieve the best health for people, animals, and the environment. In this context, Vibiosphen takes part of the efforts that are underway to develop new anti-infective therapies, to rejuvenate the antibiotic pipeline, develop novel antibiotics, and discover innovative therapeutic strategies for priority pathogens. Based on its pluridisciplinary and integrated approaches, Vibiosphen, with more than 7 years of expertise, offers support for the design of preclinical studies for the development of innovative solutions in the fight against infectious diseases.
Vibiosphen is an innovative company which provides services for pre-clinical assessments of new therapies on a broad catalogue of mouse experimental models and in vitro predictive models from standard to custom-made models.
Infectious diseases, immunomodulation, Pharmacolgy in vivo, One Health, Organoids, bacteria, virus , fungi, preclinical studies, invitro, and invivoOriginal language
From Microbes to One Health. Taylor made R&D to tackle infectious diseases.
Vibiosphen is a SME healthcare biotechnology in infectious diseases founded in 2014.
Given the important and interdependent human, animal, and environmental dimensions of antimicrobial resistance, the One Health concept promotes a global effort to achieve the best health for people, animals, and the environment. In this context, Vibiosphen takes part of the efforts that are underway to develop new anti-infective therapies, to rejuvenate the antibiotic pipeline, develop novel antibiotics, and discover innovative therapeutic strategies for priority pathogens. Based on its pluridisciplinary and integrated approaches, Vibiosphen, with more than 7 years of expertise, offers support for the design of preclinical studies for the development of innovative solutions in the fight against infectious diseases.
Vibiosphen is an innovative company which provides services for pre-clinical assessments of new therapies on a broad catalogue of mouse experimental models and in vitro predictive models from standard to custom-made models.
Preclinical studies - Vibiosphen, a CRO in infectious disease ( Bacteria - Virus - Fungi )
Studies tailored to your needs in infectious disease ( Bacteria - Virus - Fungi ) Preclinical testing with in vitro and in vivo custom models ( and referenced models)
https://www.vibiosphen.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 Eurobiomed Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Eurobiomed Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Other 12 Jul 2023 | | |
 Bpifrance Bank, Banking | Bpifrance Bank, Banking | Other 20 Apr 2023 | | |
 L'Oréal Cosmetics, Personal Care Product Manufacturing | L'Oréal Cosmetics, Personal Care Product Manufacturing | Other 20 Feb 2023 | | |
 Servier Pharmaceuticals Pharmaceutical, Pharmaceutical Manufacturing | Servier Pharmaceuticals Pharmaceutical, Pharmaceutical Manufacturing | Other 8 Nov 2022 | | |